Sedation and delirium in burn ICU
Key Points
- Delirium affects up to 47% of burn ICU patients and is independently associated with older age, intensive care, and number of interventions under anesthesia [3]
- Analgosedation strategies yield the most coma- and delirium-free days compared to deep sedation in burn patients (8 vs 3 days) [1]
- Dexmedetomidine reduces delirium rates during mechanical ventilation weaning compared to midazolam or propofol, with less need for supplemental analgesia and antipsychotics [2]
- Hospital stay is more than 13 days longer in burn patients who develop delirium, underscoring the importance of prevention strategies [3]
Overview
Sedation and delirium management in the burn ICU presents distinct challenges compared to general critical care populations. Burn patients require prolonged sedation for mechanical ventilation, repeated painful procedures, wound care, and anxiety management, yet excessive sedation prolongs ventilator days, increases delirium risk, and delays rehabilitation. Delirium in burn patients is common and multifactorial, driven by pain, systemic inflammation, repeated anesthetic exposures, opioid accumulation, sleep deprivation, and the psychological impact of disfiguring injury.
Epidemiology of Delirium in Burns
In a retrospective study of 262 adult burn patients, 51 (19%) showed signs of delirium during hospitalization [3]. The prevalence was dramatically higher among patients who received intensive care (42/89, 47%) compared to those receiving intermediate care only (9/173, 5%). Independent risk factors for delirium in multivariable regression included age over 74 years, number of operations and wound care procedures under anesthesia, and provision of intensive care (AUC 0.940) [3]. Duration of hospital stay was 13.2 days longer (95% CI 7.4-18.9, p less than 0.001) in patients who developed delirium, adjusted for age and burn size [3].
Sedation Strategy and Outcomes
Depth of Sedation
A retrospective study of 107 intubated burn ICU patients compared outcomes across three sedation depth categories: deep sedation, light sedation, and analgosedation [1]. Coma- and delirium-free days differed significantly, with analgosedation yielding the most free days and deep sedation the fewest (8 vs 3 days, p = 0.024) [1]. This difference was driven primarily by coma-free days (p = 0.00008) rather than delirium-free days. Although not statistically significant, a trend toward higher mortality in the deep sedation group was observed [1].
Dexmedetomidine
Dexmedetomidine, an alpha-2 adrenergic agonist, has demonstrated advantages in burn patient sedation. A prospective study of 56 mechanically ventilated burn patients compared dexmedetomidine to standard sedation (midazolam or propofol) during the weaning process [2]. Patients receiving dexmedetomidine had significantly lower delirium rates (38.4% on day 1 declining to 7.7% on day 5 vs 53.3% declining to 20% in the standard care group, p = 0.02), with less need for supplemental analgesia (23.1% vs 53.3%, p = 0.045) and antipsychotic agents (15.4% vs 53.3%, p = 0.01) [2]. The most notable adverse effect of dexmedetomidine was bradycardia [2].
Volatile Anesthetics for ICU Sedation
Volatile anesthetics delivered via miniature vaporizer systems represent an emerging sedation modality in the ICU. These agents provide rapid onset and offset with minimal systemic metabolism, potentially facilitating daily sedation interruption and reducing the metabolic load of intravenous sedation in burn patients [4]. No burn-specific trials of inhaled sedation have been conducted.
Assessment Tools
Delirium screening in the burn ICU relies on validated tools developed for general ICU populations. The Confusion Assessment Method for the ICU (CAM-ICU) and the Richmond Agitation-Sedation Scale (RASS) are the most widely used instruments. Burn-specific challenges to delirium assessment include the confounding effects of pain, facial burns limiting verbal communication, and hand burns limiting motor response assessment VERIFY.
Controversies and Evidence Gaps
No prospective randomized trial has compared sedation strategies head-to-head in a burn-specific population. The optimal sedation target for burn patients requiring prolonged mechanical ventilation is unknown: the general ICU trend toward lighter sedation may not account for the unique pain burden of burns. Whether dexmedetomidine should be first-line for all burn ICU patients, or reserved for specific subpopulations, remains undefined. The role of ketamine as a sedative-analgesic adjunct in burns has growing anecdotal support but limited controlled data. Delirium screening tools have not been validated specifically in burn populations, and the interplay between pain, opioid exposure, and delirium in burns makes assessment particularly complex. Long-term neurocognitive outcomes of different sedation strategies in burn survivors are unknown.
References
[1] Falksen JA et al. "Comparison of Continuous Sedatives in the Burn ICU on Delirium and Coma." J Burn Care Res 2024;45(2):410-415. PMID: 37875372 [2] Stangaciu B et al. "Sedation With Dexmedetomidine in Critically Ill Burn Patients Reduced Delirium During Weaning From Mechanical Ventilation." Cureus 2022;14(11):e31813. PMID: 36579227 [3] Abdelrahman I et al. "Development of delirium: Association with old age, severe burns, and intensive care." Burns 2020;46(4):797-803. PMID: 32183993 [4] Kopanczyk R et al. "Volatile Anesthetics: A Comprehensive Review of Pharmacology, Delivery Systems, and Safety Considerations for ICU Practitioners." Crit Care Med 2026;54(4):926-938. PMID: 41556744